Harald Hübner

Harald Hübner

Auto-generated profile, based on publicly available information

Harald Hübner

Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Science
Verified
Journal Article
Closed access
EFElissa A. Fink
Elissa A. Fink
JXJun Xu
Jun Xu
HHHarald Hübner
Harald Hübner
JBJoao M. Braz
Joao M. Braz
PSPhilipp Seemann
Philipp Seemann
PGPeter Gmeiner
Peter Gmeiner
Because nonopioid analgesics are much sought after, we computationally docked more than 301 million virtual molecules against a validated pain target, the α 2A -adrenergic receptor (α 2A AR), seeking new α 2A AR agonists chemotypes that lack the sedation conferred by known α 2A AR drugs, such as dexmedetomidine. We identified 17 ligands with potencies as low as 12 nanomolar, many with partial agonism and preferential G i and G o signaling. Experimental structures of α 2A AR complexed with two of these agonists confirmed the docking predictions and templated further optimization. Several compounds, including the initial docking hit ‘9087 [mean effective concentration (EC 50 ) of 52 nanomolar] and two analogs, ‘7075 and PS75 (EC 50 4.1 and 4.8 nanomolar), exerted on-target analgesic activity in multiple in vivo pain models without sedation. These newly discovered agonists are interesting as therapeutic leads that lack the liabilities of opioids and the sedation of dexmedetomidine.

18 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LPLior Peri
Lior Peri
DMDonna Matzov
Donna Matzov
DHDominic R. Huxley
Dominic R. Huxley
ARAlon Rainish
Alon Rainish
FFFabrizio Fierro
Fabrizio Fierro
MSMoran Shalev-Benami
Moran Shalev-Benami
Bitter taste receptors (TAS2Rs), a subfamily of G-protein coupled receptors (GPCRs) expressed orally and extraorally, elicit signaling in response to a large set of tastants. Among 25 functional TAS2Rs encoded in the human genome, TAS2R14 is the most promiscuous, and responds to hundreds of chemically diverse ligands. Here we present the cryo–electron microscopy (cryo-EM) structure of the human TAS2R14 in complex with its signaling partner gustducin, and bound to flufenamic acid (FFA), a clinically approved nonsteroidal anti-inflammatory drug. The structure reveals an unusual binding mode, where two copies of FFA are bound at distinct pockets: one at the canonical receptor site within the trans-membrane bundle, and the other in the intracellular facet, bridging the receptor with gustducin. Together with a pocket-specific BRET-based ligand binding assay, these results illuminate bitter taste signaling and provide tools for a site-targeted compound design.

15 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JHJan Hellmann
Jan Hellmann
MDMatthäus Drabek
Matthäus Drabek
JYJie Yin
Jie Yin
JGJakub Gunera
Jakub Gunera
TPTheresa Pröll
Theresa Pröll
PGPeter Gmeiner
Peter Gmeiner
Orexins are neuropeptides that activate the rhodopsin-like G protein-coupled receptors OX1R and OX2R. The orexin system plays an important role in the regulation of the sleep-wake cycle and the regulation of feeding and emotions. The nonselective orexin receptor antagonist suvorexant has been the first drug on the market targeting the orexin system and is prescribed for the treatment of insomnia. Subtype-selective OX1R antagonists are valuable tools to further investigate the functions and physiological role of the OX1R in vivo and promising lead compounds for the treatment of drug addiction, anxiety, pain or obesity. Starting from the OX1R and OX2R crystal structures bound to suvorexant, we exploited a single amino acid difference in the orthosteric binding site by using molecular docking and structure-based drug design to optimize ligand interactions with the OX1R while introducing repulsive interactions with the OX2R. A newly established enantiospecific synthesis provided ligands showing up to 75-fold selectivity for the OX1R over the OX2R subtype. The structure of a new OX1R antagonist with subnanomolar affinity (JH112) was determined by crystallography in complex with the OX1R and corresponded closely to the docking-predicted geometry. JH112 exhibits high selectivity over a panel of different GPCRs, is able to cross the blood–brain barrier and acts as slowly diffusing and insurmountable antagonist for Gq protein activation and in particular β-arrestin-2 recruitment at OX1R. This study demonstrates the potential of structure-based drug design to develop more subtype-selective GPCR ligands with potentially reduced side effects and provides an attractive probe molecule and lead compound. Significance Orexin receptors belong to the superfamily of G-protein–coupled receptors (GPCRs) which represent the largest class of drug targets in humans. Despite the recent progress in structural biology, the development of subtype-selective orexin receptor and GPCR ligands in general remains challenging, due to the high sequence similarity among individual receptor subtypes. However, subtype-selective molecules are key to discerning the individual contributions of receptor subtypes to (patho-)physiology. Starting from the clinically used, non–subtype-selective orexin receptor antagonist suvorexant, we demonstrate how docking, crystallography, medicinal chemistry, and in vitro pharmacology can be combined to exploit single amino acid sequence differences for the discovery of subtype-selective probes. Such compounds will help to better understand orexin receptor pharmacology and develop promising drug candidates.

4 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MBMarc Bathe-Peters
Marc Bathe-Peters
PGPhilipp Gmach
Philipp Gmach
HBHorst-Holger Boltz
Horst-Holger Boltz
JEJürgen Einsiedel
Jürgen Einsiedel
MGMichael Gotthardt
Michael Gotthardt
PAPaolo Annibale
Paolo Annibale
Significance: We custom synthesize a fluorescent ligand and use highly sensitive microscopy methods to show that receptors may be targeted to distinct sites of a cell. We provide microscopic images of the localization of β 1 ‐adrenergic receptors (β 1 -ARs) and β 2 ‐adrenergic receptors (β 2 ‐ARs), main drivers of the contractility of the heart, in heart muscle cells. We show that β 2 ‐ARs are exclusively targeted to specific structures in these cells, the T-tubules, while β 1 -ARs are found at the entire cell surface and in T-tubules. Such differential localization may explain their different physiological functions, even though they trigger the same biochemical signal, i.e. an increase in cyclic adenosine monophosphate (cAMP). Thus, receptor function may be determined not only by their biochemical signals, but also by their specific cellular localization.

21 March 2025 in Science Advances
Verified
Journal Article
Open access
MCMarina Casiraghi
Marina Casiraghi
HWHaoqing Wang
Haoqing Wang
PBPatrick C. Brennan
Patrick C. Brennan
CHChris Habrian
Chris Habrian
HHHarald Hübner
Harald Hübner
BKBrian K. Kobilka
Brian K. Kobilka
G protein–coupled receptors (GPCRs) exhibit varying degrees of selectivity for different G protein isoforms. Despite the abundant structures of GPCR–G protein complexes, little is known about the mechanism of G protein coupling specificity. The β 2 -adrenergic receptor is an example of GPCR with high selectivity for Gαs, the stimulatory G protein for adenylyl cyclase, and much weaker for the Gαi family of G proteins inhibiting adenylyl cyclase. By developing a Gαi-biased agonist (LM189), we provide structural and biophysical evidence supporting that distinct conformations at ICL2 and TM6 are required for coupling of the different G protein subtypes Gαs and Gαi. These results deepen our understanding of G protein specificity and bias and can accelerate the design of ligands that select for preferred signaling pathways.

4 March 2022 in Science Advances
Verified
Journal Article
Open access
JXJun Xu
Jun Xu
SCSheng Cao
Sheng Cao
HHHarald Hübner
Harald Hübner
DWDorothée Weikert
Dorothée Weikert
GCGeng Chen
Geng Chen
YDYang Du
Yang Du
The α 2A adrenergic receptor (α 2A AR) is a G protein (heterotrimeric guanine nucleotide–binding protein)–coupled receptor that mediates important physiological functions in response to the endogenous neurotransmitters norepinephrine and epinephrine, as well as numerous chemically distinct drugs. However, the molecular mechanisms of drug actions remain poorly understood. Here, we report the cryo–electron microscopy structures of the human α 2A AR-GoA complex bound to norepinephrine and three imidazoline derivatives (brimonidine, dexmedetomidine, and oxymetazoline). Together with mutagenesis and functional data, these structures provide important insights into the molecular basis of ligand recognition, activation, and signaling at the α 2A AR. Further structural analyses uncover different molecular determinants between α 2A AR and βARs for recognition of norepinephrine and key regions that determine the G protein coupling selectivity. Overall, our studies provide a framework for understanding the signal transduction of the adrenergic system at the atomic level, which will facilitate rational structure-based discovery of safer and more effective medications for α 2A AR.